James Andersen
Addiction Medicine · Eagle Lake, FLNPI 1104047695
Payments from drug & device makers
Across 1,755 payments — averaging $3056.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$1.7M
- Sanofi Pasteur Inc.$854K
- Indivior Inc.$532K
- AbbVie$522K
- Supernus Pharmaceuticals, Inc.$287K
- Novavax Inc$278K
- plus $1.1M from 21 others
Across 3 payments — averaging $1491.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
- Indivior Inc.$2K
What the payments were for
- Travel & lodging$3,01776%
- Food & beverage$97024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 1,150 | $1,749,503 |
| Sanofi Pasteur Inc. | 16 | $854,218 |
| Indivior Inc. | 139 | $531,959 |
| AbbVie(2 entities) | 123 | $521,896 |
| Supernus Pharmaceuticals, Inc. | 29 | $286,524 |
| Novavax Inc | 48 | $277,512 |
| Pfizer | 38 | $220,573 |
| Biogen | 3 | $216,129 |
| GSK | 52 | $189,835 |
| Janssen Research & Development, LLC | 28 | $87,371 |
| Eli Lilly | 7 | $78,010 |
| AstraZeneca | 6 | $57,958 |
| Johnson & Johnson | 23 | $48,816 |
| Avanir Pharmaceuticals, Inc. | 12 | $42,490 |
| E.r. Squibb & Sons, L.L.C. | 7 | $32,940 |
| Kowa Research Institute, Inc. | 24 | $32,824 |
| Genentech, Inc. | 9 | $29,715 |
| Boehringer Ingelheim | 4 | $29,613 |
| Biohaven Pharmaceuticals, Inc. | 13 | $17,712 |
| Novartis | 1 | $15,693 |
| Astrazeneca UK Limited | 2 | $12,169 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $9,632 |
| Eisai Inc. | 4 | $7,179 |
| Chiesi USA, Inc. | 4 | $7,150 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $6,000 |
| Swedish Orphan Biovitrum AB | 1 | $195 |
| Gilead | 1 | $25 |
How this compares
$5,363,642 in reported general payments places this provider in the 95th percentile of 101 addiction medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 134 | $23,882 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 16 | $18,438 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $8,672 |
| Methylphenidate Hcl | 11 | $232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $531,959 | $8,67211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 addiction medicine providers in Florida.
Other addiction medicine in Eagle Lake
- Mark GoldGainesville$355K
- Stephen StraubingGainesville$250K
- Mark JacksonSaint Augustine$225K
- David KirbyLake City$183K
- John CosbyCoral Gables$131K
- George SchroederOrmond Beach$68K
- Brian GadboisTampa$50K
- Timothy GoodenNavarre$40K
- John TannerJacksonville Beach$29K
- Malissa BarbosaOrlando$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.